| Journal of Neurology Research, ISSN 1923-2845 print, 1923-2853 online, Open Access |
| Article copyright, the authors; Journal compilation copyright, J Neurol Res and Elmer Press Inc |
| Journal website http://www.neurores.org |
Original Article
Volume 4, Number 4, August 2014, pages 97-100
Treatment of Neurodegenerative Ataxias With Intravenous Immune Globulin
Table
| Baseline | Post-infusion 1 (14 days) | Post-infusion 2 (14 days) | Post-infusion 3 (14 days) | Post-infusion 3 (28 days) | Post-infusion 3 (56 days) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Score | Score | Change from baseline | Score | Change from baseline | Score | Change from baseline | Score | Change from baseline | Score | Change from baseline | ||
| Higher scores represent greater symptoms except where noted (*). SARA: scale for the assessment and rating of ataxia. | ||||||||||||
| SARA total | Patient 1 | 20.75 | 16 | -23% | 18 | -13% | 12 | -42% | 14 | -33% | 17 | -18% |
| Patient 2 | 15.5 | 8 | -48% | 9 | -42% | 8 | -48% | 7.5 | -52% | 13 | -16% | |
| Patient 3 | 14 | 10.5 | -25% | 7 | -50% | 8 | -43% | 6 | -57% | 10.5 | -25% | |
| Gait (sub-score on SARA) | Patient 1 | 5 | 5 | 0% | 5 | 0% | 3 | -40% | 4 | -20% | 5 | 0% |
| Patient 2 | 4 | 2 | -50% | 2 | -50% | 1 | -75% | 2 | -50% | 3 | -25% | |
| Patient 3 | 4 | 2 | -50% | 2 | -50% | 2 | -50% | 2 | -50% | 3 | -25% | |
| Boston aphasia* | Patient 1 | 9 | 12 | 33% | 8 | -11% | 12 | 33% | 11 | 22% | 11 | 22% |
| Patient 2 | 7 | 7 | 0% | 8 | 14% | 11 | 57% | 12 | 71% | 12 | 71% | |
| Patient 3 | 7 | 11 | 57% | 12 | 71% | 12 | 71% | 10 | 43% | 12 | 71% | |
| PATA* | Patient 1 | 10.5 | 15 | 43% | 13.5 | 29% | 15.5 | 48% | 15.5 | 48% | 13.5 | 29% |
| Patient 2 | 9.5 | 11 | 16% | 11.5 | 21% | 12 | 26% | 11.5 | 21% | 12 | 26% | |
| Patient 3 | 8.5 | 9.5 | 12% | 12 | 41% | 13.5 | 59% | 10.5 | 24% | 11 | 29% | |
| GAITRite Walkway System: comfortable walking | ||||||||||||
| Velocity (cm/s)* | Patient 1 | 62.7 | 76.2 | 22% | 79.0 | 26% | 86.1 | 37% | 82.4 | 31% | 82.9 | 32% |
| Patient 2 | 111.9 | 119.2 | 7% | 123.3 | 10% | 118.1 | 6% | 125.0 | 12% | 115.9 | 4% | |
| Patient 3 | 109.8 | 124.6 | 13% | 127.8 | 16% | 135.2 | 23% | 128.5 | 17% | 136.8 | 25% | |
| Stride length (cm)* | Patient 1 | 96.8 | 103.5 | 7% | 114.2 | 18% | 115.6 | 19% | 110.0 | 14% | 109.5 | 13% |
| Patient 2 | 114.4 | 123.4 | 8% | 123.8 | 8% | 123.1 | 8% | 128.0 | 12% | 117.6 | 3% | |
| Patient 3 | 113.9 | 125.7 | 10% | 125.2 | 10% | 133.0 | 17% | 126.7 | 11% | 134.4 | 18% | |